How many drugs treat Malignant tumor of prostate?

Drug Landscape tracks 10 marketed treatments for Malignant tumor of prostate (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/malignant-tumor-of-prostate.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Malignant tumor of prostate — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Malignant tumor of prostate (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Malignant tumor of prostate, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Orgovyx	relugolix	MYOVANT SCIENCES	Gonadotropin Releasing Hormone Receptor Antagonist [EPC]	Gonadotropin-releasing hormone receptor	2020-01-01
Erleada	apalutamide	Johnson & Johnson		Androgen receptor	2018-01-01
Radium bromatum	RADIUM	Bayer Hlthcare			2016-01-01
Xofigo	RADIUM RA 223 DICHLORIDE	Bayer	radium Ra 223 dichloride		2013-01-01
Xtandi	xtandi	Astellas Pharma	Androgen receptor inhibitor	Androgen receptor	2012-01-01
Xtandi	enzalutamide	Astellas Pharma	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2012-01-01
Zytiga	abiraterone-acetate	Johnson & Johnson	Cytochrome P450 17A1 Inhibitor	Steroid 17-alpha-hydroxylase/17,20 lyase	2011-01-01
Taxotere	Docetaxel	Sanofi	Microtubule Inhibitor [EPC]	Growth hormone-releasing hormone receptor	1996-01-01
Zytiga	Zytiga	Bukwang Pharmaceutical		Cytochrome P450 11B2, mitochondrial, Androgen receptor, Cytochrome P450 11B1, mitochondrial
Taxotere	Taxotere	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins		Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Astellas Pharma · 2 drugs in Malignant tumor of prostate
Bayer · 2 drugs in Malignant tumor of prostate
Johnson & Johnson · 2 drugs in Malignant tumor of prostate
Bukwang Pharmaceutical · 1 drug in Malignant tumor of prostate
Fudan University · 1 drug in Malignant tumor of prostate
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 1 drug in Malignant tumor of prostate
M.D. Anderson Cancer Center · 1 drug in Malignant tumor of prostate
MYOVANT SCIENCES · 1 drug in Malignant tumor of prostate
Pfizer Inc. · 1 drug in Malignant tumor of prostate
Sanofi · 1 drug in Malignant tumor of prostate
Bayer Hlthcare · 1 drug in Malignant tumor of prostate

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Malignant tumor of prostate:

Cite this brief

Drug Landscape (2026). Malignant tumor of prostate — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malignant-tumor-of-prostate. Accessed 2026-06-10.

Malignant tumor of prostate full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing